Teneligliptin
Brand: Tenepure/Tenepride (IN/BD)
Antidiabetic
DPP-4 inhibitor
Pharmacokinetics
| Half-life | 24 hours |
| Tmax | 2 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 80 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Often dosed 20 mg od; can use 40 mg in select cases; minimal renal adjustment needed. |
⚠️ Safety & Warnings
Severity: Mild
Adverse Effects:
Nasopharyngitis, mild GI upset, rare hepatic enzyme elevation
Contraindications:
Severe hepatic impairment
Precautions:
Monitor LFTs; caution with strong CYP inhibitors/inducers